ArticleBMC cancer2026
High TLG measured by PET/CT is associated with worse PFS in patients with advanced HR+ breast cancer treated by abemaciclib combined with endocrine therapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05613270 (A Prospective Pilot Study to Explore Performance and Efficacy of 18F-FES PET/CT in ER-positive Breast Cancer Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Pilot Study to Explore Performance and Efficacy of 18F-FES PET/CT in ER-positive Breast Cancer Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThe identification of reliable biomarkers for the Cyclin-dependent kinase (CDK) 4/6 inhibitor efficacy is crucial for optimizing treatment strategies in patients with advanced hormone receptor-positive (HR+) /human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This study aimed to evaluate the prognostic value of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) parameters in patients treated with CDK4/6 inhibitor abemaciclib with endocrine therapy.
methodsWe conducted a retrospective study of patients with advanced HR+/HER2- breast cancer who received abemaciclib plus endocrine therapy and underwent 18F-FDG PET/CT examination. Parameters such as maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of PET/CT and clinicopathological parameters were assessed.
resultsA total of 72 consecutive patients were included. Most patients (79.2%) received first-line therapy. 52.8% patients received aromatase inhibitors and 47.2% received fulvestrant. The median progression-free survival (PFS) was 16.6 (95% CI: 11.3–22.0) months, while overall survival (OS) was not reached at a median follow-up of 15.4 months (interquartile range: 9.4–20.9). High baseline TLG (≥ 96.95 g) and low progesterone receptor (PR) expression (< 20%) were associated with significantly shorter PFS. A prognostic model incorporating TLG and PR expression effectively stratified patients into distinct risk groups for both PFS and OS.
conclusionHigh baseline TLG on PET/CT and low PR expression were identified as adverse prognostic factors in patients with advanced HR+ /HER2- breast cancer treated with the CDK4/6 inhibitor abemaciclib in combination with endocrine therapy.
trial registrationClinicalTrails.gov NCT05613270. Registered 28 February 2012, partly retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.